Company Overview - Chengda Pharmaceutical (SZ 301201) announced the convening of its sixth second board meeting on November 19, 2025, to discuss the proposal for the third extraordinary shareholders' meeting of 2025 [1] Financial Performance - For the year 2024, Chengda Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 55.67%, food manufacturing for 43.0%, other businesses for 0.69%, and trading revenue for 0.65% [1] - As of the report date, Chengda Pharmaceutical has a market capitalization of 8.9 billion yuan [1]

每经AI快讯，海翔药业（SZ 002099，收盘价：6.31元）11月18日晚间发布公告称，公司第八届第一次 董事会临时会议于2025年11月18日在公司会议室召开。会议审议了《关于聘任公司总经理的议案》等文 件。 每经头条（nbdtoutiao）——段睿：我与蔡磊是 "找钥匙的人"，纵使生前寻不到，也要为其他渐冻症患 者铺就近路 （记者 王晓波） 2025年1至6月份，海翔药业的营业收入构成为：医药制造业占比65.89%，染料行业占比33.09%，其他 占比1.02%。 截至发稿，海翔药业市值为102亿元。 ...

Core Viewpoint - Hualan Biological Engineering Co., Ltd. (SZ 301093) announced an investor meeting on November 18, 2025, where the company's Vice General Manager and Board Secretary Liu Xue participated in addressing investor inquiries [1] Financial Performance - For the first half of 2025, Hualan's revenue composition was 99.07% from the pharmaceutical manufacturing sector and 0.93% from other businesses [1] - As of the report date, Hualan's market capitalization stood at 7.7 billion yuan [1]

Core Viewpoint - The narrowing of the AH share premium indicates a shift in investor perception, with international capital increasingly favoring high-quality Chinese assets, leading to the possibility of H-shares surpassing A-shares in price [1][2][3] Group 1: Market Dynamics - The AH share premium has significantly narrowed compared to the same period last year, with companies like CATL, China Merchants Bank, and others experiencing instances of H-share prices exceeding A-share prices [1] - Historically, the AH premium existed due to differences in market liquidity and investor structure, with A-shares being dominated by retail investors and H-shares by institutional investors, leading to higher valuations in A-shares [1][2] - The current shift is driven by increased demand from international capital for high-quality Chinese assets and a continuous inflow of southbound funds, enhancing liquidity and valuation levels in the Hong Kong market [1][2] Group 2: Investment Trends - The direct cause of the premium inversion is the strong preference of international capital for Chinese assets, which are recognized for their stable fundamentals and growth potential [2] - Long-term capital from mainland insurance and public funds is focusing on companies' dividend capabilities and long-term growth rather than short-term fluctuations, further compressing the AH premium [2] - The premium inversion phenomenon is concentrated among two types of companies: industry leaders with global competitiveness and stable, low-volatility assets, which are the main targets for value investors [2] Group 3: Future Outlook - The current narrowing of the AH premium may be just the beginning of a shift in investor recognition, with expectations for more H-shares to exceed A-shares in price as market connectivity improves [3] - Future changes will include the integration of valuation systems, with A-shares gradually aligning with the rational pricing style of H-shares, and an increase in institutional investor participation reducing market volatility [3] - Ultimately, as investor rationality increases and company valuations converge, the prices of A-shares and H-shares should align, achieving a state of no premium and equal rights [3]

Group 1 - The core point of the news is the retirement of Ms. Pinxiang Yu, the director and CEO of Hanyu Pharmaceutical, effective November 14, 2025, due to reaching retirement age [1] - After her retirement, Ms. Pinxiang Yu will no longer hold any positions within the company or its subsidiaries [1] - For the first half of 2025, Hanyu Pharmaceutical's revenue is entirely derived from the pharmaceutical manufacturing sector, accounting for 100% of its business [1] Group 2 - As of the report, Hanyu Pharmaceutical has a market capitalization of 17.1 billion yuan [2]

Company Overview - *ST Sailong (SZ 002898) announced the resignation of Ms. Tan Haiyan as the securities affairs representative due to personal career development reasons. After her resignation, she will no longer hold any positions in the company or its subsidiaries [1] Financial Performance - For the first half of 2025, *ST Sailong's revenue composition is as follows: pharmaceutical manufacturing accounts for 59.82%, the electronics industry accounts for 39.78%, and other businesses account for 0.4% [1] - As of the report date, *ST Sailong has a market capitalization of 2.4 billion yuan [1]

Group 1 - The core technical personnel, Mr. Le Jiamin, has applied for resignation due to age and health reasons, and has completed the departure procedures, no longer holding any position in the company [1] - For the fiscal year 2024, the revenue composition of the company is as follows: 99.67% from the pharmaceutical manufacturing industry and 0.33% from other businesses [1] - The current market capitalization of the company is 2.9 billion yuan [1]

Core Viewpoint - The company has been recognized as a quality management benchmark in Guangxi for its "Practice of Granule Quality Control Team Building Experience," highlighting its commitment to quality management and operational excellence [1][6]. Group 1: Recognition and Achievements - The company successfully entered the 2025 Guangxi Industrial Enterprise Quality Management Benchmark list, receiving formal recognition and a plaque from the Guangxi Industrial and Information Technology Department [1]. - This recognition follows the team's previous achievement of the "National Worker Pioneer" title in 2023, showcasing the effectiveness of its quality management practices [7]. Group 2: Quality Management Practices - The granule production team operates under a "Precision, Standardization, and Refinement" GMP management system, aiming for zero defects through strict adherence to quality standards [6]. - The team has achieved a 100% training qualification rate for all employees, enhancing their technical skills and quality awareness [6]. - The team maintains quality standards that exceed national regulations, with moisture content controlled below 2% compared to the national standard of ≤8% [7]. Group 3: Future Plans and Goals - The company plans to leverage this recognition to further promote the granule production team's practices across all departments, aiming for higher standards in quality control and innovation [7]. - The company is committed to contributing to the high-quality development of Guangxi's industry by enhancing product and service quality [7].

Group 1 - The core point of the article is that *ST Sailong has received approval from the National Medical Products Administration for its injectable Nicorandil product, which is a significant development for the company [1] - As of January to June 2025, *ST Sailong's revenue composition is as follows: 59.82% from the pharmaceutical manufacturing sector, 39.78% from the electronics sector, and 0.4% from other businesses [1] - The current market capitalization of *ST Sailong is 2.3 billion yuan [1]

Group 1 - The core point of the article is that Borui Pharmaceutical (SH 688166) held its 15th meeting of the 4th Board of Directors on November 13, 2025, to review proposals related to external investments and related transactions [1] - For the year 2024, Borui Pharmaceutical's revenue composition is 97.33% from the pharmaceutical manufacturing industry and 2.67% from other businesses [1] - As of the report date, Borui Pharmaceutical has a market capitalization of 23.2 billion yuan [1]